ArticleLangmuir : the ACS journal of surfaces and colloids2026
Enhancing the Hemocompatibility of 3D-Printable Silicone Elastomers for Artificial Lung Applications.
Article in Langmuir : the ACS journal of surfaces and colloids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Clinical hollow-fiber artificial lungs are prone to clotting, necessitating the use of systemic anticoagulation and thus increasing the risk of bleeding events. This study seeks to address these limitations by creating hemocompatible and biomimetic 3D-printed artificial lungs. This study investigates the nonthrombogenic effects of imbuing a polydimethylsiloxane (PDMS or silicone elastomer)-based 3D-printable resin with hydrophilic molecules with the goal of reducing the body's natural coagulation response to foreign materials, increasing device lifetime, and reducing systemic anticoagulation, thereby coming closer to mimicking the native in vivo blood interface. First, contact angle (hydrophilicity) tests were done to narrow down the number of candidate modifications for the development of a high-resolution PDMS resin for vat photopolymerization (VPP). Then, dynamic blood flow-through testing was performed using a high-resolution PDMS base resin modified by (1) adding 1% 2-methacryloyloxyethyl phosphorylcholine (MPC) to the base resin; (2) adding 1.8% poly(ethylene glycol) methacrylate (PEGMA) to the base resin; or (3) infusing the neat PDMS devices with 2% dimethylsiloxane-[60-70% ethylene oxide] (PEO-PDMS) in ethanol post printing. Biomimetic microfluidic capillary devices designed in SOLIDWORKS were 3D-printed via VPP, cleared of uncured resin, and tested for coagulation with freshly drawn ovine whole blood. Devices (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.